Jordan A. Stinson

ORCID: 0000-0003-3281-3172
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Veterinary Oncology Research
  • Cancer Research and Treatments
  • Sarcoma Diagnosis and Treatment
  • Virus-based gene therapy research
  • Cell Adhesion Molecules Research
  • Immunotherapy and Immune Responses
  • Angiogenesis and VEGF in Cancer
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • CAR-T cell therapy research
  • Nausea and vomiting management
  • Cancer Immunotherapy and Biomarkers
  • Phagocytosis and Immune Regulation
  • Cancer Treatment and Pharmacology
  • Neuroscience and Neural Engineering
  • Photoreceptor and optogenetics research
  • Pathogenesis and Treatment of Hiccups
  • Silk-based biomaterials and applications
  • Chemokine receptors and signaling
  • Nanoplatforms for cancer theranostics
  • Retinal Diseases and Treatments
  • Anesthesia and Pain Management
  • Immune Cell Function and Interaction
  • Neutropenia and Cancer Infections
  • EEG and Brain-Computer Interfaces
  • Advancements in Transdermal Drug Delivery

Massachusetts Institute of Technology
2021-2024

Allen Institute
2024

McGovern Institute for Brain Research
2021

Harvard–MIT Division of Health Sciences and Technology
2021

Vaxess Technologies (United States)
2020-2021

Sunnybrook Health Science Centre
2014-2018

Health Sciences Centre
2014-2018

University of Toronto
2015-2017

Tufts University
2015-2016

Abstract Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves antitumor immune responses in preclinical studies, clinical success has been limited by on-target, off-tumor activity. Here, we report the development a tumor-anchored ɑ4-1BB (ɑ4-1BB-LAIR), which consists antibody fused to collagen-binding protein LAIR. While combination treatment an (TA99) shows only modest efficacy, simultaneous depletion CD4+ boosts cure rates over 90% mice....

10.1038/s41467-024-45625-0 article EN cc-by Nature Communications 2024-03-01

Microneedles represent an exciting departure from the existing parenteral injection paradigm for drug delivery, particularly administration of vaccines. While benefit delivering vaccine antigens to immunocompetent tissue in skin has been established, there have varying degrees success using microneedles do so. Here, we investigate use silk fibroin protein produce and evaluate their ability deliver vaccines against influenza, Clostridium difficile, Shigella. Fibroin silkworm Bombyx mori...

10.1021/acsbiomaterials.6b00515 article EN ACS Biomaterials Science & Engineering 2016-12-29

Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic; however, long-term benefit is limited to a subset of patients for select cancer indications. The incomplete understanding their mechanism action has hindered efforts at improvement, with conflicting hypotheses proposing either antagonism CTLA-4:B7 axis or Fc effector-mediated regulatory T cell (Treg) depletion governing efficacy. Here, we report engineering nonantagonistic CTLA-4 binding domain (b1s1e2)...

10.1073/pnas.2300895120 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2023-07-24

Systemically administered cytokines are potent immunotherapeutics but can cause severe dose-limiting toxicities. To overcome this challenge, have been engineered for intratumoral retention after local delivery. However, despite inducing regression of treated lesions, tumor-localized often elicit only modest responses at distal untreated tumors. In the present study, we report a localized cytokine therapy that safely elicits systemic antitumor immunity by targeting ubiquitous leukocyte...

10.1038/s41590-024-01925-7 article EN cc-by Nature Immunology 2024-08-07

<div>Abstract<p>Although heightened intratumoral levels of reactive oxygen species (ROS) are typically associated with a suppressive tumor microenvironment, under certain conditions ROS contribute to elimination. Treatment approaches, including some chemotherapy and radiation protocols, increase cancer cell that influence their mechanism death subsequent recognition by the immune system. Furthermore, activated myeloid cells rapidly generate upon encounter pathogens or infected...

10.1158/1535-7163.c.7606530 preprint EN 2025-01-02

Cytokine therapies such as IL2 and IL12 suffer from impractically small therapeutic windows driven by their on-target, off-tumor activity, limiting clinical potential despite potent antitumor effects. We previously engineered cytokines that bind anchor to tumor collagen following intratumoral injection, sought test safety biomarker activity in spontaneous canine soft-tissue sarcomas (STS).Collagen-binding were canine-ized minimize immunogenicity used a rapid dose-escalation study healthy...

10.1158/1078-0432.ccr-23-0006 article EN Clinical Cancer Research 2023-04-04

Corticosteroids are used adjuvant to certain chemotherapy regimens, either as an antiemetic, reduce other side effects, or enhance cancer treatment. Additionally, they frequently for symptom control in patients with end stage disease. Corticosteroid use may induce hyperglycemia approximately 20-50% of patients, which negatively affect patient outcomes.To determine the frequency blood glucose monitoring and without diabetes receiving continuous corticosteroids chemotherapy, incidence...

10.3978/j.issn.2224-5820.2015.04.07 article EN PubMed 2015-04-01

Catalase is an antioxidant enzyme that catalyzes the rapid conversion of hydrogen peroxide to water and oxygen. Use catalase as a cancer therapeutic has been proposed reduce oxidative stress hypoxia in tumor microenvironment, both activities which are hypothesized growth. Furthermore, exposing murine tumors exogenous was previously reported have benefit. We studied effect tumor-localized catalases with aim further elucidate mechanism action. To do this, we engineered two approaches maximize...

10.1016/j.redox.2023.102766 article EN cc-by Redox Biology 2023-06-05

Background: While the efficacy of olanzapine in prophylaxis chemotherapy-induced nausea and vomiting (CINV) has been documented, literature on use as a rescue medication for breakthrough CINV scarce. The following study retrospectively evaluated safety treatment CINV. prophylactic setting was also examined smaller cohort. Methods: Electronic medical records adult patients aged >17 years receiving prescription from Odette Cancer Centre Pharmacy at Sunnybrook Hospital between January 2013 June...

10.21037/apm.2016.04.05 article EN Annals of Palliative Medicine 2016-05-20

Thermal drawing has been recently leveraged to yield multifunctional, fiber-based neural probes at near kilometer length scales. Despite its promise, the widespread adoption of this approach impeded by (1) material compatibility requirements and (2) labor-intensive interfacing functional features external hardware. Furthermore, in multifunctional fibers, significant volume is occupied passive polymer cladding that so far only served structural or electrical insulation purposes. In article,...

10.1021/acscentsci.1c00592 article EN cc-by ACS Central Science 2021-08-28

Cytokines IL2 and IL12 exhibit potent anticancer activity but suffer a narrow therapeutic window due to off-tumor immune cell activation. Engineering cytokines with the ability bind associate tumor collagen after intratumoral injection potentiated response without toxicity in mice was previously safe pet dogs sarcoma. Here, we sought test efficacy of this approach advanced melanoma.

10.1158/1078-0432.ccr-24-0861 article EN Clinical Cancer Research 2024-07-09
Coming Soon ...